- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06168942
Estudo Laminar LAAX Pivotal IDE
Estudo Pivotal IDE de Eliminação Laminar do Apêndice Atrial Esquerdo (LAAX)
The purpose of this study is to compare the safety and effectiveness of Laminar Left Atrial Appendage Closure (LAAC) device as compared to the commercially available LAAC devices in participants with non-valvular atrial fibrillation (NVAF) to reduce the risk of stroke (blocked blood vessel or bleeding in brain) and systemic embolism (blockage in a blood vessel harming vital organs).
Visão geral do estudo
Status
Descrição detalhada
This prospective, randomized, controlled, multicenter, open-label pivotal clinical study will enroll participants with non-valvular atrial fibrillation who are eligible for short-term anticoagulation therapy but have a rationale to seek non-pharmacologic alternative. Participants will be randomized 1:1 to the Laminar Left Atrial Appendage Closure System or commercially available device (WATCHMAN™ left atrial appendage closure device / Amulet™ left atrial appendage occluder).
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35243
- Grandview Medical Center
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85018
- Arizona Arrhythmia Research Group Phoenix Cardio Research Group PCRG
-
Tucson, Arizona, Estados Unidos, 85712
- Tucson Medical Center
-
-
Arkansas
-
Jonesboro, Arkansas, Estados Unidos, 72401
- Arrhythmia Research Group
-
-
California
-
Los Angeles, California, Estados Unidos, 90048
- Cedars Sinai Medical Center
-
Palo Alto, California, Estados Unidos, 94303
- Stanford Health Care
-
Rancho Cordova, California, Estados Unidos, 95670
- Univeristy of California Davis Health
-
San Diego, California, Estados Unidos, 92121
- Scripps Health
-
Santa Monica, California, Estados Unidos, 90404
- Providence Saint John's Health Center and the Pacific Heart Institute
-
Thousand Oaks, California, Estados Unidos, 91360
- Los Robles Regional Medical Center
-
-
Florida
-
North Naples, Florida, Estados Unidos, 34102
- NCH Healthcare
-
Sarasota, Florida, Estados Unidos, 34239
- Sarasota Memorial Hospital
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory University
-
Atlanta, Georgia, Estados Unidos, 30309
- Piedmont Healthcare
-
Savannah, Georgia, Estados Unidos, 31404
- Memorial Health University Medical Center
-
-
Kansas
-
Overland Park, Kansas, Estados Unidos, 66211
- The Kansas City Heart Rhythm Institute
-
Wichita, Kansas, Estados Unidos, 67214
- Ascension via Christi Hospitals Wichita Inc
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40503
- Baptist Health Lexington
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
-
New York
-
Bay Shore, New York, Estados Unidos, 11706
- Northwell Health
-
New York, New York, Estados Unidos, 10029
- Icahn School of Medicine at Mount Sinai
-
New York, New York, Estados Unidos, 10016
- NYU Langone Health
-
New York, New York, Estados Unidos, 10032
- Columbia University in the City of New York and The New York and Presbyterian Hospital
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28203
- Wake Forest University Health Sciences
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- Lindner Clinical Trial Center/Christ Hospital
-
Cincinnati, Ohio, Estados Unidos, 45202
- Bethesda North Hospital Trihealth
-
Columbus, Ohio, Estados Unidos, 43210
- Ohio State University
-
Columbus, Ohio, Estados Unidos, 43214
- Ohio Health
-
-
South Carolina
-
North Charleston, South Carolina, Estados Unidos, 29406
- Trident Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Vanderbilt University Medical Center
-
Nashville, Tennessee, Estados Unidos, 37203
- Centennial Medical Center
-
-
Texas
-
Austin, Texas, Estados Unidos, 78705
- Texas Cardiac Arrhythmia Research Foundation
-
Shenandoah, Texas, Estados Unidos, 77380
- Heart Rhythm Associates
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98122
- Swedish Medical Center
-
Tacoma, Washington, Estados Unidos, 98405
- St Joseph Hospital and Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Documented evidence of paroxysmal, persistent, or permanent non-valvular atrial fibrillation (NVAF)
- CHA2DS2-VASc score greater than or equal to (>=) 2 in men and >= 3 in women
- Deemed to be clinically indicated for left atrial appendage (LAA) closure by the Site Investigator and a clinician not a part of the procedural team using an evidence-based decision-making tool in accordance with standard of care
- Recommended for chronic oral anticoagulation therapy (OAC) but has an appropriate rationale to seek a non-pharmacologic alternative
- Eligible for the protocol-specified post-procedural antithrombotic regimen
- Willing and able to comply with the protocol, and has provided written informed consent (participant or legally authorized representative) per institutional review board (IRB) requirements
Exclusion Criteria:
- Single episode, transient, or reversible atrial fibrillation (AF) (example, secondary to thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures)
- Prior cardiac surgery or any procedure that involved pericardial access
- Stage IV kidney disease or Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) less than (<) 30 milliliters per minute per (mL/min)/1.73 square meters (m^2) or participants with end stage renal disease who are dialysis dependent
- Any cardiac or non-cardiac interventional or surgical procedures within 60 days prior to or any planned general surgery, cardiac surgery, or interventional procedure within 60 days after implant (including, but not limited to cardioversion, percutaneous coronary intervention (PCI), cardiac ablation, cataract surgery)
- Left atrial appendage anatomy which cannot accommodate either commercially available control device or the laminar implant per manufacturer instructions for use (IFU) (that is, the anatomy and sizing must be appropriate for a control and the Laminar device to be enrolled in the study)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Laminar Device
Participants will be treated with the Laminar Left Atrial Appendage Closure System. |
Treatment with the Laminar Left Atrial Appendage Closure System. |
|
Comparador Ativo: Control left atrial appendage closure (LAAC)
Participants will be treated with a commercially-available LAAC device. |
Treatment with a WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
All-Cause Mortality
Prazo: Up to 12 months
|
Composite rate of all-cause mortality will be reported. |
Up to 12 months
|
|
Number of Participants With Major Bleeding According to the Bleeding Academic Research Consortium (BARC) Type III or V
Prazo: Up to 12 months
|
The number of participants with major bleeding, according to the BARC type III or V, will be reported. Type III
Type V
|
Up to 12 months
|
|
Number of Participants With Pericardial Effusion Requiring Drainage
Prazo: Up to 12 months
|
Participants with pericardial effusion requiring drainage will be reported. Pericardial effusion is defined as 1) Clinically non-relevant: requiring no intervention, treated pharmacologically and 2) Clinically relevant: treated with therapeutic intervention (pericardiocentesis, surgical intervention, blood transfusion) and/or result in shock or death. |
Up to 12 months
|
|
Number of Participants With Device Embolization
Prazo: Up to 12 months
|
Participants with device embolization will be reported. Device embolization is defined as movement of a medical device to an unintended location within the body with resulting obstruction of an organ or vessel. |
Up to 12 months
|
|
Number of Participants With Device or Procedure-Related Events Requiring Open Cardiac Surgery or Major Endovascular Intervention
Prazo: Up to 12 Months
|
Participants with device or procedure-related events requiring open cardiac surgery or major endovascular intervention will be reported. |
Up to 12 Months
|
|
Number of Participants Reporting Ischemic Stroke or Systemic Embolism
Prazo: Up to 18 Months
|
Participant reporting ischemic stroke or systemic embolism will be reported. Systemic embolism is defined as acute vascular insufficiency or occlusion of the extremities or any non-CNS organ associated with clinical, imaging, surgical/autopsy evidence of arterial occlusion in the absence of other likely mechanism (example; trauma, atherosclerosis, or instrumentation). |
Up to 18 Months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants With Peri-Device Flow
Prazo: Up to 12 Months
|
Peri-Device flow is defined as >= 3 mm in width which communicates beyond the device into the body of the left atrial appendage) per transesophageal echocardiogram (TEE) evaluated by independent core laboratory. |
Up to 12 Months
|
|
Rate of Device-Related Thrombosis
Prazo: Up to 12 Months
|
Device related thrombosis is defined as density attached to the implanted LAAC device in echocardiographic or computer tomography imaging. |
Up to 12 Months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Saibal Kar, MD, Los Robles Health System
- Investigador principal: Devi Nair, MD, St. Bernards Heart and Vascular Center
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- LAM202403
- CL-0059 (Outro identificador: Laminar, Inc.)
- LAM202403 (Outro identificador: Biosense Webster, Inc.)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .